EPIDEMIOLOGY OF ADVANCED LUNG-DISEASE IN THE UNITED-STATES

Authors
Citation
Ea. Bresnitz, EPIDEMIOLOGY OF ADVANCED LUNG-DISEASE IN THE UNITED-STATES, Clinics in chest medicine, 18(3), 1997, pp. 421
Citations number
46
Categorie Soggetti
Respiratory System
Journal title
ISSN journal
02725231
Volume
18
Issue
3
Year of publication
1997
Database
ISI
SICI code
0272-5231(1997)18:3<421:EOALIT>2.0.ZU;2-5
Abstract
Advanced lung disease (ALD) may be defined as a chronic, nonmalignant lung disease that permanently impairs activities of daily living. Defi ned in that fashion, the term encompasses the severe end of the spectr um of many common and unusual lung diseases, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), sarcoidos is, the pneumoconioses, idiopathic pulmonary fibrosis, and pulmonary h ypertension. Like ''end-stage kidney disease,'' the term advanced lung disease is useful clinically because supportive treatment is similar regardless of the original cause of organ injury. Many, but not all, p atients with ALD are disabled. ALD is identified by a physician on the basis of history, physical examination, and appropriate diagnostic st udies, and is related to functional impairment. Disability is determin ed by an insurance administrator or administrative law judge and, in a dults, is related to ability to work.(42) Mortality statistics maintai ned by the National Center for Health Statistics (NCHS) indicate that COPD and allied conditions are the fifth leading cause of death in the United States, after heart disease, cancer, accidents, and neurologic disease(12) (Fig. 1). There was a 46.6% increase in the death rate fo r chronic lung disease from 1979 to 1993, and a 7.5% increase from 199 2 to 1993.(12) The mortality statistics probably underestimate the mor tality attributable to ALD because many individuals who are severely i mpaired by smoking related chronic lung diseases actually die of other causes, notably heart disease or cancer.(44) This review focuses on U S data, although the burden of ALD worldwide obviously is more substan tial. The NCHS is the principal source of information on morbidity and mortality in the United States. It-obtains information through severa l population-based surveys of representative samples of specific data sources(45) (Table 1). Each of the surveys conducted by the NCHS provi des data that are used to estimate some measure of disease incidence o r prevalence, health care utilization rate, or death rate. Data are es timated and reported principally for diseases with high incidences, su ch as asthma and COED. Data on more rare conditions, such as CF, are g enerally obtained from disease registries (when they exist), or from l arge health care delivery databases, such as health maintenance organi zations. Regardless of the source of information, it is not always pos sible to determine the distribution of illness severity from databases . As a result, many are less useful for assessing the extent of ALD, a s previously defined.